Emily M. Leproust Sells 546 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 546 shares of the firm’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $45.59, for a total value of $24,892.14. Following the completion of the transaction, the chief executive officer now owns 672,518 shares in the company, valued at $30,660,095.62. The trade was a 0.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Twist Bioscience Price Performance

Shares of TWST stock opened at $45.12 on Thursday. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The firm has a market cap of $2.68 billion, a PE ratio of -12.53 and a beta of 1.85. The company has a 50-day moving average of $46.26 and a two-hundred day moving average of $46.47.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Scotiabank raised their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Leerink Partners boosted their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. TD Cowen reissued a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Wolfe Research initiated coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus target price of $51.90.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently made changes to their positions in TWST. State Street Corp raised its position in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares during the period. Geode Capital Management LLC raised its holdings in shares of Twist Bioscience by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after buying an additional 26,145 shares during the period. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience during the 3rd quarter worth about $43,992,000. Wellington Management Group LLP boosted its holdings in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares during the period. Finally, Fred Alger Management LLC grew its position in Twist Bioscience by 17.1% in the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock valued at $34,660,000 after acquiring an additional 112,272 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.